Testosterone therapy, association with age, initiation and mode of therapy with cardiovascular events: a systematic review

Clinical Endocrinology

Volumn 85, Issue 3, 2016, Pages 436-443

  Albert, Stewart G ^a   Morley, John E ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LIPID; TESTOSTERONE;

AGE; ANDROGEN DEFICIENCY; ANDROGEN THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE DURATION; HUMAN; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TESTOSTERONE BLOOD LEVEL;

EID: 84982111790     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.13084     Document Type: Article

References (24)

1. Bhasin, S., Cunningham, G.R., Hayes, F.J. et al. (2010) Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 95, 2536–2559.
2. Morgentaler, A., Miner, M.M., Caliber, M. et al. (2015) Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clinic Proceedings, 90, 224–251.
3. Haddad, R.M., Kennedy, C.C., Caples, S.M. et al. (2007) Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clinic Proceedings, 82, 29–39.
4. Corona, G., Maseroli, E., Rastrelli, G. et al. (2014) Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis expert opin. Drug Safety, 13, 1327–1351.
5. Finkle, W.D., Greenland, S., Ridgeway, G.K. et al. (2014) Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS ONE, 9, e85805.
6. Vigen, R., O'Donnell, C.I., Barón, A.E. et al. (2013) Association of testosterone therapy with mortality, myocardial Infarction, and Stroke in Men With Low Testosterone Levels. JAMA, 310, 1829–1836.
7. Testosterone Products: Drug Safety Communication - FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use [03-03-2015] http://www.fda.gov/Drugs/DrugSafety/ucm436259.htm.
8. Xu, L., Freeman, G., Cowling, B. et al. (2013) Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Medicine 11, 108. http://www.biomedcentral.com/1741-7015/11/108.
9. Borst, S.E., Shuster, J.J., Zou, B. et al. (2014) Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis. BMC Medicine, 12, 211. http://www.biomedcentral.com/1741-7015/12/211.
10. Copenhagen Study Group for Liver Diseases (1986) Testosterone treatment of men with alcoholic cirrhosis: a double-blind study: the Copenhagen Study Group for Liver Diseases. Hepatology, 6, 807–813.
11. Behre, H.M., von Eckardstein, S., Kliesch, S. et al. (1999) Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years. Clinical Endocrinology, 50, 629–635.
12. Guyatt, G.H., Oxman, A.D. & Vist, G.E. (2008) et al for the GRADE Working Group GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 336, 924–926.
13. Bax, L., Yu, L.M., Ikeda, N. et al. (2006) Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Medical Research Methodology, 6, 50.
14. Bax, L. MIX 2.0. Professional software for meta-analysis in Excel. Version (2.0.1.4). (2011) BiostatXL, http://www.meta-analysis-made-easy.com.
15. Borenstein, M., Hedges, L.V., Higgins, J.P.T et al. (2009) Introduction to Meta-analysis WileyWest Sussex, United Kingdom.
16. Deeks, JJ., Higgins, J.P.T. & Altman, D.G. (editors). Chapter 9: analysing data and undertaking meta-analyses. In: Higgins, J.P.T. & Green S eds Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
17. Hulley, S., Grady, D., Bush, T. et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA, 280, 605–613.
18. Shlipak, M.G, Chaput, L.A., Vittinghoff, E. et al. (2003) For the Heart and estrogen/progestin replacement Study (HERS) investigators estrogen/progestin replacement study (HERS). Lipid changes on hormone therapy and coronary heart disease events in the heart and estrogen/progestin replacement study (HERS). American Heart Journal, 146, 870–875.
19. Chou, T.M., Sudhir, K., Hutchison, S.J. et al. (1996) Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo. Circulation, 94, 2614–2619.
20. Jones, R.D., English, K.M., Jones, T.H. et al. (2004) Testosterone-induced coronary vasodilation occurs via a non-genomic mechanism: evidence of direct calcium antagonism action. Clinical Science, 107, 149–158.
21. Anderson, R.A., Ludlam, C.A. & Wu, F.C. (1995) Thrombosis and haemostasis: haemostatic effects of supraphysiological levels of testosterone in normal men. Thrombosis and Haemostsis 75, 693–697.
22. 2 receptor density and aggregation responses. Circulation, 91, 2742–2747.
23. Drinka, P. (2013) Hematocrit elevation associated with testosterone administration. Journal of the American Medical Directors Association, 14, 848.
24. Morley, J.E. (2013) Hypogonadism, testosterone and nursing home residents. Journal of the American Medical Directors Association, 14, 381–383.